cough/diarrhea

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter

TECHNICAL FIELD The present disclosure relates to certain heterocycle fused morphianans. Compounds of the present disclosure are mixed mu agonist delta antagonists or dual mu agonist/delta agonists or antagonists at mu, delta and kappa opioid receptors. Compounds of the present disclosure are useful

BACKGROUND OF THE INVENTION This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the

BACKGROUND OF THE INVENTION This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives

FIELD OF THE INVENTION This invention relates to infectious diseases and, more specifically, to inhibitors of bacterial toxins of the type having a catalytic A subunit and a cell-binding B subunit and, especially to those within this group which function as ADP-ribosylating toxins. BACKGROUND OF THE

FIELD OF THE INVENTION This invention relates to infectious diseases and, more specifically, to inhibitors of bacterial toxins of the type having a catalytic A subunit and a cell-binding B subunit and, especially to those within this group which function as ADP-ribosylating toxins. BACKGROUND OF THE

BACKGROUND OF THE INVENTION 1. Technical Field This invention relates generally to diarylmethylpiperazine compounds useful as mu and/or delta receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug

TECHNICAL FIELD This invention relates to morphinan compounds useful as .mu., .kappa. and/or .delta. receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder

TECHNICAL FIELD This invention relates to morphinan compounds useful as .mu., .kappa. and/or .delta. receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel, essentially enantiomerically pure diarylmethylpiperazine compound having utility as a receptor-binding species, e.g., as a mu and/or delta receptor opioid compound mediating analgesia; as a therapeutic